BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
路透社2026/10/08 16:11Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Latest Developments
October 8 - ** Pacira BioSciences (PCRX.O) shares surged 44%, hitting a three-year high of 36.30 USD
** If the rally persists, PCRX is set to record its largest single-day gain in history
**Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences for $1.65 billion in cash ((link)), at a price of $36.50 per share
** The offer represents a premium of about 44.8% over Pacira's recent closing price of $25.20
** The deal will add Pacira’s non-opioid pain drugs Exparel and Zilretta to Viatris’ product portfolio
** Viatris shares fell 2.6%, closing at $17.04
** JPMorgan stated: "We believe this acquisition will not markedly alter VTRS’s overall financial profile in the short or long term, and we expect sales of Exparel to gradually decline from 2030 onwards due to the entry of generics."
** Both parties expect the deal to be completed by the end of 2026
**Including intraday volatility, PCRX has risen 40.2% year-to-date, while VTRS has climbed 36.8%
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for readers’ convenience only. Reuters accepts no responsibility for any damage or loss resulting from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
